Citations

Mayo Clinic

Showing 10 of 108551 citations.

Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients
Choudry, Mouneeb, Dindinger‐Hill, Kassandra , Ambrose, Jacob , Horns, Joshua J. , Vehawn, Jeffrey , Gill, Hailie , Murray, Nicole , Hunt, Trevor C. , Haaland, Benjamin , O’Neil, Brock B., Murray, Nicole Z , Chipman, Jonathan , Martin, Christopher B. , Chipman, Jonathan, Hanson, Heidi A.

Cancer Medicine | March 13, 2024 | Volume: 13 | Issue: 5 | Pages: No page available

10.1002/cam4.7058 | PMID 38477496 Get It

Abstract Introduction Patients living in rural areas have worse cancer‐specific outcomes. This study examines the effect of family‐based social capital on genitourinary cancer survival. We hypothesized that rural patients with urban relatives have improved survival relative to rural patients without urban family. Methods We examined rural and urban based Utah individuals diagnosed with genitourinary cancers between 1968 and 2018. Familial networks were determined using the Utah Population Database. Patients and relatives were classified as rural or urban based on 2010 rural–urban commuting area codes. Overall survival was analyzed using Cox proportional hazards models. Results We identified 24,746 patients with genitourinary cancer with a median follow‐up of 8.72 years. Rural cancer patients without an urban relative had the worst outcomes with cancer‐specific survival hazard ratios (HRs) at 5 and 10 years of 1.33 (95% CI 1.10–1.62) and 1.46 (95% CI 1.24–1.73), respectively relative to urban patients. Rural patients with urban first‐degree relatives had improved survival with 5‐ and 10‐year survival HRs of 1.21 (95% CI 1.06–1.40) and 1.16 (95% CI 1.03–1.31), respectively. Conclusions Our findings suggest rural patients who have been diagnosed with a genitourinary cancer have improved survival when having relatives in urban centers relative to rural patients without urban relatives. Further research is needed to better understand the mechanisms through which having an urban family member contributes to improved cancer outcomes for rural patients. Better characterization of this affect may help inform policies to reduce urban–rural cancer disparities.
Longitudinal Free‐Water Changes in Dementia with Lewy Bodies
Chiu, Shannon , Chen, Robin , Wang, Wei‐en , Armstrong, Melissa J. , Savica, Rodolfo , Fields, Julie A. , Graff‐Radford, Neill R., Ferman, Tanis J. , Kantarci, Kejal , Vaillancourt, David E. , Initiative, Alzheimer's Disease Neuroimaging, Chiu, Shannon Y , Savica, Rodolfo , Kantarci, Kejal , Ferman, Tanis J , Armstrong, Melissa J , Boeve, Bradley F. , Ramanan, Vijay K. , Graff‐Radford, Neill R. , Initiative, Alzheimer's Disease Neuroimaging

Movement Disorders | March 13, 2024 | Volume: 39 | Issue: 5 | Pages: 836-846

10.1002/mds.29763 | PMID 38477399 Get It

AbstractBackgroundDiffusion‐weighted magnetic resonance imaging (dMRI) examines tissue microstructure integrity in vivo. Prior dementia with Lewy bodies (DLB) diffusion tensor imaging studies yielded mixed results.ObjectiveWe employed free‐water (FW) imaging to assess DLB progression and correlate with clinical decline in DLB.MethodsBaseline and follow‐up MRIs were obtained at 12 and/or 24 months for 27 individuals with DLB or mild cognitive impairment with Lewy bodies (MCI‐LB). FW was analyzed using the Mayo Clinic Adult Lifespan Template. Primary outcomes were FW differences between baseline and 12 or 24 months. To compare FW change longitudinally, we included 20 cognitively unimpaired individuals from the Alzheimer's Disease Neuroimaging Initiative.ResultsWe followed 23 participants to 12 months and 16 participants to 24 months. Both groups had worsening in Montreal Cognitive Assessment (MoCA) and Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) scores. We found significant FW increases at both time points compared to baseline in the insula, amygdala, posterior cingulum, parahippocampal, entorhinal, supramarginal, fusiform, retrosplenial, and Rolandic operculum regions. At 24 months, we found more widespread microstructural changes in regions implicated in visuospatial processing, motor, and cholinergic functions. Between‐group analyses (DLB vs. controls) confirmed significant FW changes over 24 months in most of these regions. FW changes were associated with longitudinal worsening of MDS‐UPDRS and MoCA scores.ConclusionsFW increased in gray and white matter regions in DLB, likely due to neurodegenerative pathology associated with disease progression. FW change was associated with clinical decline. The findings support dMRI as a promising tool to track disease progression in DLB. © 2024 International Parkinson and Movement Disorder Society.
Multimorbidities and Tuberculosis: A Multidisciplinary, Integrated Care Model Is the Way Forward
Nair, MRaveendran

Pulmon | March 13, 2024 | Volume: 25 | Issue: 2 | Pages: 35-37

10.4103/pulmon.pulmon_26_23 Get It

Aberrant TIMP‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma
Duch, Paula , Díaz‐Valdivia, Natalia , Gabasa, Marta , Ikemori, Rafael , Arshakyan, Marselina , Llorente, Alejandro , Teixidó, Cristina , Pereda, Javier , Chuliá‐Peris, Lourdes , Teixido, Cristina , Radisky, Derek C. , Alcaraz, Jordi , Fernández‐Nogueira, Patricia , Ramírez, José , Galbis, Jose Marcelo , Hilberg, Frank , Reguart, Noemı́ , Díaz-Valdivia, Natalia

Cancer Science | March 13, 2024 | Volume: 115 | Issue: 5 | Pages: 1505-1519

10.1111/cas.16141 | PMID 38476010 Get It

AbstractThe fibrotic tumor microenvironment is a pivotal therapeutic target. Nintedanib, a clinically approved multikinase antifibrotic inhibitor, is effective against lung adenocarcinoma (ADC) but not squamous cell carcinoma (SCC). Previous studies have implicated the secretome of tumor‐associated fibroblasts (TAFs) in the selective effects of nintedanib in ADC, but the driving factor(s) remained unidentified. Here we examined the role of tissue inhibitor of metalloproteinase‐1 (TIMP‐1), a tumor‐promoting cytokine overproduced in ADC‐TAFs. To this aim, we combined genetic approaches with in vitro and in vivo preclinical models based on patient‐derived TAFs. Nintedanib reduced TIMP‐1 production more efficiently in ADC‐TAFs than SCC‐TAFs through a SMAD3‐dependent mechanism. Cell culture experiments indicated that silencing TIMP1 in ADC‐TAFs abolished the therapeutic effects of nintedanib on cancer cell growth and invasion, which were otherwise enhanced by the TAF secretome. Consistently, co‐injecting ADC cells with TIMP1‐knockdown ADC‐TAFs into immunocompromised mice elicited a less effective reduction of tumor growth and invasion under nintedanib treatment compared to tumors bearing unmodified fibroblasts. Our results unveil a key mechanism underlying the selective mode of action of nintedanib in ADC based on the excessive production of TIMP‐1 in ADC‐TAFs. We further pinpoint reduced SMAD3 expression and consequent limited TIMP‐1 production in SCC‐TAFs as key for the resistance of SCC to nintedanib. These observations strongly support the emerging role of TIMP‐1 as a critical regulator of therapy response in solid tumors.
Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex
Hirman, Joe, Lipton, Richard B. , Lipton, R.B. , Porreca, Frank , Navratilova, Edita , MaassenVanDenBrink, Antoinette , Dodick, David W.

Cephalalgia | March 13, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1177/03331024241238153 | PMID 38477313 Get It

Background Women show increased prevalence and severity of migraine compared to men. Whether small molecule calcitonin gene-related peptide receptor (CGRP-R) antagonists (i.e., gepants) and monoclonal antibodies targeting either the CGRP-R or the CGRP peptide might show sexually dimorphic outcomes for acute and preventive therapy has not been established. Methods We conducted a subpopulation analysis of available published data from FDA reviews to evaluate potential sex differences in the response rates of ubrogepant, rimegepant and zavegepant for acute migraine therapy. Available data from FDA reviews of erenumab, fremanezumab, galcanezumab and eptinezumab, approved CGRP-R and CGRP monoclonal antibodies and of atogepant were examined for prevention outcomes based on patient sex. Preventive outcomes were analyzed separately for patients with episodic migraine and chronic migraine. Results In women, the three approved gepants produced statistically significant drug effects regardless of dose tested on the FDA mandated co-primary endpoints, the proportion of patients achieving two-hour pain-freedom and the proportion of patients free of their most bothersome symptom at two hours post-dose. In women, the average placebo-subtracted two-hour pain-freedom proportion was 9.5% (CI: 7.4 to 11.6) and the average numbers needed to treat was 11. The free from most bothersome symptom at two hours outcomes were also significant in women. The gepant drugs did not reach statistically significant effects on the two-hour pain-freedom endpoint in the men, with an average drug effect of 2.8% (CI: −2.5 to 8.2) and an average number needed to treat of 36. For freedom from most bothersome symptom at two hours post-dose endpoint, differences were not significant in male patients. The treatment effect in each of the gepant studies was always numerically greater in women than in men. In evaluation of prevention outcomes with the antibodies or atogepant using the change from the specified primary endpoint (e.g., monthly migraine days), the observed treatment effect for episodic migraine patients almost always favored drug over placebo in both women and men. For chronic migraine patients the treatment effects of antibodies were similar in men and women and always favored the drug treated group. Conclusion/Interpretation: Small molecule CGRP-R antagonists are effective in acute migraine therapy in women but available data do not demonstrate effectiveness in men. CGRP-targeting therapies are effective for migraine prevention in both male and female episodic migraine patients but possible sex differences remain uncertain. In male and female chronic migraine patients, CGRP/CGRP-R antibodies were similarly effective. The data highlight possible differential effects of CGRP targeted therapies in different patient populations and the need for increased understanding of CGRP neurobiology in men and women.
Artificial-Intelligence-Based Clinical Decision Support Systems in Primary Care: A Scoping Review of Current Clinical Implementations
Gomez-Cabello, Cesar A. , Borna, Sahar , Pressman, Sophia M. , Haider, Syed Ali , Haider, Clifton R. , Forte, Antonio J. , Pressman, Sophia , Forte, Antonio Jorge , Borna, Sahar , Gomez-Cabello, Cesar A , Haider, Syed A

European Journal of Investigation in Health, Psychology and Education | March 13, 2024 | Volume: 14 | Issue: 3 | Pages: 685-698

10.3390/ejihpe14030045 | PMID 38534906 Get It

Primary Care Physicians (PCPs) are the first point of contact in healthcare. Because PCPs face the challenge of managing diverse patient populations while maintaining up-to-date medical knowledge and updated health records, this study explores the current outcomes and effectiveness of implementing Artificial Intelligence-based Clinical Decision Support Systems (AI-CDSSs) in Primary Healthcare (PHC). Following the PRISMA-ScR guidelines, we systematically searched five databases, PubMed, Scopus, CINAHL, IEEE, and Google Scholar, and manually searched related articles. Only CDSSs powered by AI targeted to physicians and tested in real clinical PHC settings were included. From a total of 421 articles, 6 met our criteria. We found AI-CDSSs from the US, Netherlands, Spain, and China whose primary tasks included diagnosis support, management and treatment recommendations, and complication prediction. Secondary objectives included lessening physician work burden and reducing healthcare costs. While promising, the outcomes were hindered by physicians’ perceptions and cultural settings. This study underscores the potential of AI-CDSSs in improving clinical management, patient satisfaction, and safety while reducing physician workload. However, further work is needed to explore the broad spectrum of applications that the new AI-CDSSs have in several PHC real clinical settings and measure their clinical outcomes.
Hamstring Tendon Autograft Is Associated With Increased Knee Valgus Moment After Anterior Cruciate Ligament Reconstruction: A Biomechanical Analysis
Vij, Neeraj , Glattke, Kaycee , Vaughn, Jeffrey L., Brinkman, Joseph C. , Winters, Jenni, Brennan, Amber, Zhao, Sixue, Tokish, John M. , Menzer, Heather , Glattke, Kaycee E , Tummala, Sailesh V , Tummala, Sailesh V. , Vij, Neeraj, Salehi, Hadi, Chhabra, Anikar

The American Journal of Sports Medicine | March 13, 2024 | Volume: 52 | Issue: 5 | Pages: 1220-1228

10.1177/03635465241233705 | PMID 38476007 Get It

Background: There is limited evidence related to the effects of autograft type on functional performance after anterior cruciate ligament reconstruction (ACLR). Purpose/Hypothesis: This study aimed to compare biomechanical outcomes during a drop vertical jump (DVJ) between patients with a hamstring tendon (HT) autograft, quadriceps tendon (QT) autograft with bone block, QT autograft without bone block, and bone–patellar tendon–bone autograft at 6 months postoperatively in an adolescent population. The authors’ hypothesized there would be differences in DVJ biomechanics between athletes depending on the type of autograft used. Study Design: Controlled laboratory study. Methods: Patients aged 8 to 18 years who underwent primary ACLR were included for analysis. Kinematic and kinetic data collected during a DVJ using a 3-dimensional computerized marker system were assessed at 6 months after ACLR and compared with the uninjured contralateral limb. Results: A total of 155 participants were included. There were no significant differences in terms of age, sex, or affected leg ( P≥ .1973) between groups. The HT group was significantly associated with a larger knee valgus moment at initial contact compared with the QT group (28 × 10 –2 vs −35 × 10 –2 N·m/kg, respectively; P = .0254) and a significantly larger maximum hip adduction moment compared with the QT with bone block group (30 × 10 –2 vs −4 × 10 –2 N·m/kg, respectively; P = .0426). Both the QT with bone block (–12 × 10 –2 vs −3 × 10 –2 N·m/kg, respectively; P = .0265) and QT (–13 × 10 –2 vs −3 × 10 –2 N·m/kg, respectively; P = .0459) groups demonstrated significantly decreased mean knee extension moments compared with the HT group. Conclusion: The findings of this study suggest that utilizing an HT autograft resulted in a significantly increased knee valgus moment at initial contact compared with a QT autograft without bone block at 6 months after ACLR in adolescent patients performing a DVJ. A QT autograft was found to be associated with significantly decreased extensor mechanism function compared with an HT autograft. Clinical Relevance: This study adds unique kinematic and kinetic information regarding various ACLR autograft options and highlights the biomechanical deficits that should be taken into consideration in rehabilitation.
Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women
Dugani, Sagar B. , Moorthy, M. Vinayaga , Demler, Olga , Li, Chunying , Glynn, Robert J. , Mora, Samia , Dugani, Sagar B , Mora, Samia , Ridker, Paul M.

Clinical Chemistry | March 12, 2024 | Volume: 70 | Issue: 5 | Pages: 768-779

10.1093/clinchem/hvae007 | PMID 38472127 Get It

Abstract Background Premature coronary heart disease (CHD) is a major cause of death in women. We aimed to characterize biomarker profiles of women who developed CHD before and after age 65 years. Methods In the Women’s Health Study (median follow-up 21.5 years), women were grouped by age and timing of incident CHD: baseline age <65 years with premature CHD by age 65 years (25 042 women; 447 events) and baseline age ≥65 years with nonpremature CHD (2982 women; 351 events). Associations of 44 baseline plasma biomarkers measured using standard assays and a nuclear magnetic resonance (NMR)-metabolomics assay were analyzed using Cox models adjusted for clinical risk factors. Results Twelve biomarkers showed associations only with premature CHD and included lipoprotein(a), which was associated with premature CHD [adjusted hazard ratio (HR) per SD: 1.29 (95% CI 1.17–1.42)] but not with nonpremature CHD [1.09(0.98–1.22)](Pinteraction = 0.02). NMR-measured lipoprotein insulin resistance was associated with the highest risk of premature CHD [1.92 (1.52–2.42)] but was not associated with nonpremature CHD (Pinteraction <0.001). Eleven biomarkers showed stronger associations with premature vs nonpremature CHD, including apolipoprotein B. Nine NMR biomarkers showed no association with premature or nonpremature CHD, whereas 12 biomarkers showed similar significant associations with premature and nonpremature CHD, respectively, including low-density lipoprotein (LDL) cholesterol [1.30(1.20–1.45) and 1.22(1.10–1.35)] and C-reactive protein [1.34(1.19–1.50) and 1.25(1.08–1.44)]. Conclusions In women, a profile of 12 biomarkers was selectively associated with premature CHD, driven by lipoprotein(a) and insulin-resistant atherogenic dyslipoproteinemia. This has implications for the development of biomarker panels to screen for premature CHD.
Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept
Imazio, Massimo , Klein, Allan L. , Brucato, Antonio , Abbate, Antonio , Arad, Michael , Cremer, Paul , LeWinter, Martin M. , Lewis, Basil S. , Lin, David , Sutej, Paul, Wasserstrum, Yishay , Clair, JoAnn , Agarwal, Indra, Wang, Sheldon, Paolini, John F. , Investigators, for the RHAPSODY, Cremer, Paul C , LeWinter, Martin M , Lewis, Basil S , Luis, Sushil A , Wasserstrum, Yishay , Clair, JoAnn , Paolini, John F , Brucato, Antonio , Klein, Allan , Imazio, Massimo , Insalaco, Antonella , Luis, Sushil Allen , Nicholls, Stephen J. , Investigators, for the RHAPSODY

Journal of the American Heart Association | March 12, 2024 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/jaha.123.032516 | PMID 38471825 Get It

Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long‐term extension further explored recurrent pericarditis natural history and treatment duration decision‐making during 24 additional months of open‐label rilonacept treatment. Methods and Results Seventy‐four patients commenced the long‐term extension, with a median (maximum) total rilonacept duration of 22 (35) months. Individually, 18 months after the most proximal pericarditis recurrence, investigators decided to continue rilonacept on study, suspend rilonacept for off‐treatment observation (rescue allowed), or discontinue the study. The annualized incidence of pericarditis recurrence on rilonacept up to the 18‐month decision milestone was 0.04 events/patient‐year versus 4.4 events/patient‐year prestudy while on oral therapies. At the 18‐month decision milestone, 64% (33/52) continued rilonacept, 15% (8/52) suspended rilonacept for observation, and 21% (11/52) discontinued the study. Among the 33 patients (1/33; 3.0%) continuing rilonacept (median time to recurrence could not be estimated due to too few events), a single recurrence occurred 4 weeks after a treatment interruption. Among patients suspending rilonacept, 75% (6/8) experienced recurrence (median time to recurrence, 11.8 weeks [95% CI, 3.7 weeks to not estimable]). There was a 98% reduction in risk of pericarditis recurrence among patients continuing rilonacept treatment after the 18‐month decision milestone versus those suspending treatment for observation (hazard ratio, 0.02; P <0.0001). Conclusions In the RHAPSODY long‐term extension, continued rilonacept treatment resulted in continued response; treatment suspension at the 18‐month decision milestone was associated with pericarditis recurrence. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03737110.